Compare ENB & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENB | MRNA |
|---|---|---|
| Founded | 1949 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.7B | 91.2B |
| IPO Year | 1998 | 2018 |
| Metric | ENB | MRNA |
|---|---|---|
| Price | $47.61 | $223.15 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 24 | 23 |
| Target Price | $50.86 | ★ $158.47 |
| AVG Volume (30 Days) | 4.2M | ★ 13.6M |
| Earning Date | 11-06-2026 | 11-06-2026 |
| Dividend Yield | ★ 5.81% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ 1.99 | N/A |
| Revenue | ★ $65,194,000,000.00 | $19,263,000,000.00 |
| Revenue This Year | $40.44 | $24.04 |
| Revenue Next Year | N/A | $10.63 |
| P/E Ratio | $24.18 | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $45.03 | $22.28 |
| 52 Week High | $58.45 | $280.80 |
| Indicator | ENB | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 45.65 | 49.76 |
| Support Level | $46.38 | $181.02 |
| Resistance Level | $49.62 | $254.48 |
| Average True Range (ATR) | 0.73 | 18.70 |
| MACD | -0.08 | -2.24 |
| Stochastic Oscillator | 36.67 | 43.41 |
Enbridge owns extensive midstream assets that transport hydrocarbons across the US and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also operates regulated natural gas utilities in the US and Canada, including Canada's largest natural gas distribution company. The firm has a small renewable energy portfolio primarily focused on onshore and offshore wind projects.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.